B-cell receptor immunoglobulin idiotype (BCR idiotype)

The B-cell receptor (BCR) immunoglobulin idiotype represents the unique set of antigenic determinants located within the variable regions (V-regions) of the heavy and light chains of the immunoglobulin molecule expressed by a specific clone of B-cells. In the context of B-cell malignancies, such as follicular lymphoma, all malignant cells within a single patient typically express an identical, unique BCR idiotype, which functions as a truly tumor-specific neoantigen (Levy et al., 2011, Blood). This high degree of specificity makes the idiotype an ideal target for personalized immunotherapy, particularly idiotype vaccines designed to elicit a patient-specific immune response against the lymphoma. These vaccines are produced by isolating the patient's unique tumor idiotype and conjugating it to an immunogenic carrier protein to overcome the low immunogenicity of the self-derived protein. While clinical trials for vaccines like BiovaxID have demonstrated the potential to extend disease-free survival in specific patient subsets, the logistical challenges of custom manufacturing for every individual remain a significant barrier to widespread clinical adoption (Schuster et al., 2011, Journal of Clinical Oncology). Beyond active vaccination, the BCR idiotype is also explored as a target for passive immunotherapy using anti-idiotype antibodies and experimental CAR-T cell therapies aimed at precise tumor eradication without affecting the healthy B-cell population (Kwak et al., 1992, New England Journal of Medicine).

Other names

Tumor-specific idiotypeId antigenImmunoglobulin idiotypeB-cell receptor variable regionClonal idiotype

Active immunotherapy involving the administration of patient-specific idiotype proteins, typically conjugated to a carrier protein such as Keyhole Limpet Hemocyanin (KLH) and administered with an adjuvant (e.g., GM-CSF), to stimulate a host cytotoxic T-cell and B-cell immune response against the unique clonal immunoglobulin expressed on the surface of malignant B-cells (Schuster et al., 2011, Journal of Clinical Oncology).